{"id":"NCT00094497","sponsor":"Collaborative Group for Adrenocortical Carcinoma Treatment","briefTitle":"Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)","officialTitle":"First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2004-10-20","resultsPosted":"2016-09-21","lastUpdate":"2016-09-21"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Adrenal Cortical"],"interventions":[{"type":"DRUG","name":"Etoposide","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Streptozotocin","otherNames":[]},{"type":"DRUG","name":"Mitotane","otherNames":[]}],"arms":[{"label":"EDP-M","type":"ACTIVE_COMPARATOR"},{"label":"Sz-M","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"every 8 weeks until death up to 5 years","effectByArm":[{"arm":"EDP-M","deltaMin":108,"sd":null},{"arm":"Sz-M","deltaMin":124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":11},"locations":{"siteCount":32,"countries":["United States","Australia","Austria","France","Germany","Italy","Netherlands","Sweden"]},"refs":{"pmids":["22551107"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":86,"n":148},"commonTop":[]}}